4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
10.70
-0.49 (-4.38%)
At close: Dec 5, 2025, 4:00 PM EST
10.91
+0.21 (1.96%)
After-hours: Dec 5, 2025, 7:24 PM EST
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $90.00K in the quarter ending September 30, 2025, with 2,900.00% growth. This brings the company's revenue in the last twelve months to $120.00K, up 605.88% year-over-year. In the year 2024, 4D Molecular Therapeutics had annual revenue of $37.00K, down -99.82%.
Revenue (ttm)
$120.00K
Revenue Growth
+605.88%
P/S Ratio
5,094.54
Revenue / Employee
$529
Employees
227
Market Cap
611.35M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FDMT News
- 14 days ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - 4DMT to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 19 days ago - 4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewsWire
- 21 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 26 days ago - 4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 4 weeks ago - 4DMT to Participate in Jefferies 2025 London Healthcare Conference - GlobeNewsWire
- 4 weeks ago - 4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - 4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years - GlobeNewsWire